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Despite existing federal and state law and regulation, new human subjects research (HSR) scandals involving “vulnerable” popu-
lations continue to surface.1 Although existing over-
sight mechanisms were enacted to ensure voluntary 
informed consent for participants and institutional 
review board (IRB) oversight of HSR, these laws 
and regulations do not provide any special oversight 
mechanisms or protections to ensure the ethical and 
safe inclusion of cognitively impaired adults. The 
absence of rules to ensure consistently ethical conduct 
of research involving adults who lack consent capacity 
may either lead to exploitation of this vulnerable pop-
ulation or the dearth of important research into the 
broad range of diseases that impair cognition. In other 
words, while some institutions and investigators are 
conducting research with this group without guidance, 
others are taking an extremely conservative approach 
and are excluding these individuals from research. 
Without safeguards that are adequate and robust but 
not overly burdensome, conducting research involving 
this population is ethically and legally challenging. 
In the state of New York, efforts have been made to 
regulate research involving individuals who lack con-
sent capacity, particularly in response to the state’s 
checkered history of ensuring the protection of this 
particular population.2 In 1990, the New York State 
Office of Mental Health promulgated regulations to 
govern research that occurs at its facilities. However, 
these regulations were overturned because a New York 
State court held that the agency did not have author-
ity to make rules to oversee human subjects research. 
Eight years later, the New York State Department of 
Health – the agency with the authority to promulgate 
regulations governing HSR – commissioned a work 
group to develop regulations authorizing research 
involving individuals with decisional incapacity. How-
ever, for political and other reasons, these proposed 
regulations were never acted upon.
In January 2014, the New York State Task Force 
on Life and the Law released its Report and Recom-
mendations for Research with Human Subjects Who 
Lack Consent Capacity, in an effort to ensure the ethi-
cal conduct of research involving cognitively impaired 
adults. The report is the result of a multi-year effort to 
respond to appeals for guidance from New York State 
IRBs, investigators, and research institutions on how 
to conduct ethical research involving adults who lack 
consent capacity. It represents the most recent step in 
a decades-long process across New York State agen-
cies and courts to develop oversight mechanisms that 
are appropriately sensitive to the fine line between 
protecting a vulnerable population and impeding the 
advancement of research.
As a practical matter, the Task Force’s report may 
have limited direct application. The report – and, for 
that matter, any New York State action – only applies 
to human subjects research conducted in the state 
that is not subject to federal oversight. The federal 
Common Rule governs human subjects research that 
is supported by federal funding, is conducted by the 
federal government, or is overseen by a federal agency 
— in other words, the vast majority of human subjects 
research conducted in the United States. New York 
State’s Public Health Law only applies to research 
not covered by federal law.3 Thus, the Act applies to a 
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minority of research activity in the state, because most 
research conducted in New York is either federally 
funded or otherwise subject to federal oversight.4 
I. OMH Regulations and T.D. v. N.Y. State 
Office of Mental Health
To address the lack of oversight of research involving 
individuals who lack consent capacity in New York 
State, in 1990 the New York State Office of Mental 
Health (OMH), the state agency that supervises psy-
chiatric facilities, promulgated regulations intended 
to allow residents of OMH facilities — both adults and 
minors — who lack consent capacity to participate in 
research protocols. The regulations’ stated purpose 
was to “ensure the protection of patients who par-
ticipate in research while simultaneously facilitating 
research into the very disorders from which they suffer 
and which underlie their impairment.”5 Six patients 
who had been adjudicated mentally incapable of giv-
ing or withholding consent to participate in medical 
research brought an action against OMH challeng-
ing the regulations.6 The district court found that 
the regulations had been improperly promulgated 
by OMH because the New York State Department of 
Health had the exclusive responsibility of overseeing 
all human subjects research in New York.
OMH appealed, and the appellate court upheld the 
district court’s finding that OMH did not have author-
ity to promulgate regulations governing human sub-
jects research. The court went further, however, and 
held that the regulations violated the due process 
clauses of the New York State Constitution and the 
Fourteenth Amendment of the U.S. Constitution, as 
well as the state’s common law rights to privacy and 
personal autonomy. This latter holding was based on 
the finding that the OMH regulations failed to provide 
for adequate notice and review procedures for indi-
viduals who were found to lack consent capacity and 
could be enrolled in research protocols. Moreover, the 
court found that by permitting research that involved 
more than minimal risk, the regulations struck an 
improper balance between the “interests of research-
ers and the rights of the subjects.”7
One year later, the highest New York court held that 
the section of the appellate court’s decision related to 
the constitutional and common law rights of individu-
als who lack consent capacity was an “inappropriate 
advisory opinion.”8 Thus, only the court’s reason-
ing that OMH was not authorized to oversee human 
subjects research in New York State is still good law. 
Nevertheless, many state agencies — even outside of 
New York — have been hesitant to provide guidance 
or regulations to include individuals who lack consent 
capacity in research due to concern that courts assess-
ing the validity of new regulations would impose simi-
lar requirements in the future.
II. New York State Advisory Work Group on 
Research Involving the Protected Classes 
In response to the T.D. litigation, in 1998, the New 
York State Department of Health commissioned an 
advisory work group to develop regulations autho-
rizing research involving individuals with decisional 
incapacity and to address the concept of surrogate 
consent to research. The work group released a draft 
report entitled Recommendations on the Oversight 
of Human Subject Research Involving the Protected 
Classes (the NYSAWG report).9 The report proposed 
specific and substantial regulatory language for the 
Department of Health, including investigator and IRB 
responsibilities, requirements for informed consent, 
procedures for assessing capacity of potential research 
subjects, surrogate authorization, use of research 
advance directives, special safeguards to protect the 
rights and well-being of research subjects, and report-
ing requirements. Specifically, it recommended allow-
ing surrogate consent to certain kinds of research that 
offers no prospect of direct benefit presenting “mini-
mal risk” or a “minor increase over minimal risk,” and 
allowing participation in research that offers no pros-
pect of direct benefit presenting “more than a minor 
increase over minimal risk” in special circumstances 
with additional safeguards in place.
The report was distributed to over 500 interested 
parties for comment. Although the Department of 
Health considered revisions to the report in response 
to comments and the final decision in T.D., revised 
recommendations were never released. In 2000, the 
resignation of the former Commissioner of Health, 
Barbara Ann DeBuono, and appointment by Gover-
nor Pataki of a successor, Antonia C. Novello, “who 
would naturally require time to familiarize herself 
with the issues,” led to a “delay” in taking next steps 
with the proposed regulations.10 Further, “sharp criti-
cism from both advocates and researchers,” including 
the state Medical Society (“a powerful lobbying group 
in Albany”11), was credited for state inaction.12 The 
Department of Health never acted on the report, nor 
did it promulgate any regulations regarding the con-
duct of human subjects research in New York State.
III. The Task Force on Life and the Law’s 
Report and Recommendations for Research with 
Human Subjects Who Lack Consent Capacity
In the absence of rules at both the federal and state 
level to ensure consistently ethical conduct of research 
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involving adults lacking consent capacity, IRBs, inves-
tigators, research institutions, and other stakeholders 
appealed to the New York State Department of Health 
for guidance on how to conduct research involving this 
vulnerable population. The Department of Health, in 
turn, asked the New York State Task Force on Life and 
the Law (the Task Force) to analyze the legal and ethi-
cal dimensions of allowing adults who lack consent 
capacity in research protocols subject to New York 
State oversight. Established by Executive Order in 
1985, the Task Force is composed of approximately 23 
Governor-appointed leaders in the fields of religion, 
philosophy, law, medicine, nursing, and bioethics. 
The Task Force began its endeavor in December 
2007 by disseminating a survey to approximately 
300 New York IRB chairs and members. The survey 
requested information about institutions’ practices, if 
any, for conducting research involving the cognitively 
impaired, and views on the regulatory landscape. 
More than 100 responses provided a detailed and use-
ful qualitative account of research practices in New 
York and indicated a need for guidelines to ensure 
consistently ethical research practices.
In its examination of the issues associated with 
research involving cognitively impaired adults, the Task 
Force reviewed medical and policy literature on human 
subjects research, informed consent, surrogate consent, 
capacity assessment, risk-benefit analysis, research pro-
tections, adverse events, and related topics. It conducted 
extensive legal research of federal and state regula-
tory standards, including New York’s, and case studies 
pertaining to human subjects research involving the 
cognitively impaired. The Task Force analyzed previ-
ously-released reports, recommendations, and draft 
regulations on human subjects research by the Depart-
ment of Health and the public comments to these efforts, 
including the NYSAWG report. It also took into account 
the controversial advisory opinion in T.D., in which the 
court addressed the need for special protections where 
research includes individuals who lack consent capacity. 
Noting its advisory rather than controlling status, the 
Task Force focused on the court’s emphasis on research 
subjects’ autonomy and dignitary rights.
To address the significant inconsistency in the over-
sight and conduct of research involving individuals 
who lack consent capacity, the Task Force drafted a set 
of legal and ethical guidelines regarding the conduct 
of research in New York State involving this particular 
population.13 An underlying goal of the work was to 
ensure that research protocols are available to cogni-
tively impaired individuals so that they may reap the 
benefits of research and share its risks and burdens 
like their non-cognitively impaired peers, while also 
ensuring the appropriate level of protections. 
Unlike the NYSAWG report, which proposed the 
promulgation of specific regulations pursuant to New 
York State law,14 the Task Force’s report proposed 
guidance — recommendations for IRBs, investigators, 
institutions, and legally authorized representatives 
(LARs) for the ethical conduct of research involving 
individuals who lack consent capacity. The Task Force 
encouraged voluntary adherence to these recommen-
dations for all human subjects research involving 
adults lacking full consent capacity conducted in New 
York State. Moreover, in developing its guidance, the 
Task Force considered and declined to recommend 
legislation governing research involving individuals 
who lack consent capacity. It concluded that because 
existing law permits research involving this popula-
tion, no statutory change was needed.  
In its report, the Task Force made a number of 
important and, in some cases, unique recommenda-
tions regarding adults who lack consent capacity in 
human subjects research. For one, in the past, surro-
gate consent to research in New York State was lim-
ited because of uncertainty about who could provide 
surrogate consent to participation. The Task Force’s 
report relied on the 2010 passage of the Family Health 
In the absence of rules at both the federal and state level to ensure consistently 
ethical conduct of research involving adults lacking consent capacity, IRBs, 
investigators, research institutions, and other stakeholders appealed to the 
New York State Department of Health for guidance on how to conduct research 
involving this vulnerable population. The Department of Health, in turn, asked 
the New York State Task Force on Life and the Law (the Task Force) to analyze 
the legal and ethical dimensions of allowing adults who lack consent capacity  
in research protocols subject to New York State oversight.
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Care Decisions Act (FHCDA), which changed the 
legal landscape by permitting surrogate consent to 
health care. The surrogate hierarchy contained in the 
statute thus opened up the field of research requiring 
surrogate consent in New York State.15 
In addition, and probably most importantly, the 
Task Force recommended that, in rare circumstances, 
adults who lack consent capacity may be enrolled in 
research that presents more than a minor increase over 
minimal risk that offers no prospect of direct benefit, 
provided that a number of significant safeguards and 
protections are in place.16 In such cases, for research 
with a minor increase over minimal risk and no pros-
pect of direct benefit to the participant, the Task Force 
recommended that IRBs may approve such studies 
only if the research is vitally important to further the 
understanding of the etiology, prevention, diagnosis, 
pathophysiology, or alleviation or treatment of a con-
dition or disorder that affects the research popula-
tion, and if the risks are reasonable in relation to the 
research’s “vital importance.” Furthermore, IRBs may 
approve such studies only if they require mandatory 
rigorous procedures and oversight for enrollment and 
monitoring of participants through the use of safe-
guards, including an independent consent monitor 
(ICM) and a medically responsible clinician (MRC). 
For research with more than a minor increase over 
minimal risk and no prospect of direct benefit to the 
participant, IRBs may approve such studies in only 
two circumscribed circumstances: where the poten-
tial participants have a previously executed research 
advance directive or in special situations with notifica-
tion to the Department of Health and use of a special 
review panel. 
The latter circumstance would require an alterna-
tive approval process consisting of several steps: (1) 
IRB review, (2) Department of Health notification by 
the IRB and possible referral by the Department of 
Health to a special review panel, and (3) an IRB deci-
sion to approve or reject the research protocol. For a 
protocol to be considered under this alternative pro-
cess, the IRB must first examine whether the research 
is of vital importance. In addition, although this type 
of research protocol must be labeled as offering no 
prospect of direct benefit, for some research partici-
pants, a remote possibility exists that they may ben-
efit from the research or from the knowledge gained. 
In such cases, the IRB must consider whether this 
remote possibility of benefit exists for potential par-
ticipants and weigh it against the potential risks of the 
protocol. Furthermore, the IRB should ensure that the 
study requires rigorous procedures and oversight for 
enrollment and monitoring of participants through 
the use of safeguards, including an ICM and MRC. 
Under step two of the process, the IRB should 
notify the Department of Health.  At its discretion, 
the Department may: (1) reject the study (and thus 
the research could not be approved by the IRB), (2) 
approve the study (whereby the research could be 
approved by the IRB), or (3) convene a special review 
panel of experts who will examine the study and issue 
recommendations to the IRB on whether the study 
should be approved.17 If the Department of Health 
decides that a special review panel must examine the 
protocol, after the special panel has made its recom-
mendations, the Department should refer the pro-
tocol back to the IRB for review, and the IRB will 
make the final determination based on the panel’s 
recommendations.
Further, acknowledging the appellate court’s opin-
ion in T.D., the Task Force recognized that a potential 
research participant should be notified and allowed 
the opportunity for review of all decisions to involve 
him or her in research, including assessments of 
capacity. The Task Force emphasized the importance 
of procedures for providing notice to the poten-
tial research participant and, if necessary, the LAR, 
regarding the capacity assessment and opportunities 
for objection and review. Researchers should provide 
notice to the potential participant and/or LAR that an 
assessment will be conducted and the consequences 
(if any) of a determination of incapacity. Providing 
notice promotes transparency by alleviating any con-
cerns that an individual might be involved in research 
without the knowledge of the participant or LAR. It 
also demonstrates respect for the prospective partici-
pant by presenting an opportunity for the individual 
or his/her LAR to object to either the capacity assess-
ment or the results of the evaluation. When capacity 
assessments are contested, the most ethical alterna-
tive may be to decline to enroll the individual in the 
research protocol. However, in some cases, alterna-
tives short of non-enrollment could appropriately deal 
with any objection, such as a second capacity assess-
ment. Readily available review procedures allow indi-
viduals an opportunity to request further information 
or a second opinion where they or their LARs see fit. 
Furthermore, steps should be taken during the notifi-
cation process to ensure that the results of the capacity 
assessment remain confidential and that the privacy 
of the individual is respected. 
Conclusions
Although existing New York State law governs human 
subjects research for a subset of research conducted 
in the state by providing mechanisms for ensuring 
voluntary informed consent for participants and IRB 
review of research protocols, it does not provide any 
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special oversight mechanisms for research involving 
adults who lack consent capacity. Despite calls to do 
so, federal law also does not provide safeguards or 
special protections for research involving “mentally 
disabled persons.”18 The absence of such guidelines or 
regulations may lead to unethical or unsafe research 
protocols or the dearth of important research into the 
broad range of diseases that impair cognition. Despite 
the continued absence of rules at both the federal and 
state level to ensure consistently ethical conduct of 
research involving adults lacking 
consent capacity, such research 
continues “in the shadow of the 
law.”19 While some institutions 
and investigators are conducting 
research with this population with-
out oversight or guidance, others 
are taking an extremely conserva-
tive approach and are excluding 
these individuals from research, 
citing concerns about vulnerability 
and exploitation. Without appro-
priately protective but not overly 
burdensome safeguards, this will 
remain a challenge to the conduct 
of ethical research.
Guidance like the Task Force’s 
report is becoming increasingly 
necessary. In its survey of New York IRB chairs and 
members, the Task Force found that, in the absence of 
clear guidance, institutions either abstained entirely 
from research that required surrogate consent or 
engaged in such research despite the lack of clear 
authority. Beyond New York, research involving indi-
viduals who lack consent capacity occurs, even with-
out legal or regulatory oversight. Laws that explicitly 
authorize research with incapacitated individuals 
are isolated exceptions; in the vast majority of states, 
research with individuals who lack consent capacity 
continues without any noticeable oversight, including 
regarding who may consent to research on behalf of 
the incapacitated participant. As of 2008, nine states 
had statutes that specifically allow family members to 
give proxy consent on behalf of their incompetent fam-
ily members to participate in research, although some 
of these jurisdictions restrict the use of proxy consent 
to certain populations or certain types of research.20
Various commentators have opined on the “unsuc-
cessful” proposals of the federal, New York, and Mary-
land commissions that, in the late 1990s, made recom-
mendations for the inclusion of cognitively impaired 
individuals in research.21 Like the Task Force’s cur-
rent recommendations, all three past reports “agreed 
that no-direct-benefit studies involving more than 
minimal risks should be permissible under some 
circumstances.”22 To the extent that the Task Force’s 
recommendations deviate from past reports and the 
“inappropriate advisory opinion” in T.D., they seek to 
offset concerns with proposals for significant addi-
tional safeguards and oversight mechanisms. 
The Task Force’s report may be better received than 
past recommendations for two reasons. First, since 
the state’s previous efforts to regulate research involv-
ing the cognitively impaired, a few other states have 
passed laws authorizing research with incapacitated 
persons.23 A handful of states have passed laws specifi-
cally authorizing research with incapacitated persons, 
including California, New Jersey, Virginia, Oklahoma, 
and Wyoming.24 Nevertheless, most current laws only 
authorize surrogate consent to research without enu-
merating any significant safeguards. Second, although 
regulatory oversight mechanisms may be more effec-
tive in ensuring consistent and uniform protections of 
individuals who lack consent capacity in research, the 
framing of the report as guidance, rather than manda-
tory rules, may make the recommendations more pal-
atable — at least initially — to investigators, research 
institutions, IRBs, and other stakeholders. Policy 
makers may eventually seek to enact mandatory regu-
latory oversight mechanisms, based on observations 
of the success (or lack thereof) of the guidelines.
The Task Force’s recommendations may also serve 
as a model for research policy in other states and at 
the federal level. Importantly, they are more com-
prehensive and propose more significant safeguards 
for research involving individuals who lack consent 
capacity than existing federal and state oversight 
mechanisms. Thus, for entities that previously did not 
pursue research with adults lacking consent capacity, 
the report endeavors to provide the foundation that 
Thus, for entities that previously did not pursue 
research with adults lacking consent capacity, the 
report endeavors to provide the foundation that 
will enable them to pursue research protocols that 
will lead to a better understanding of conditions 
that impair cognition. For those who already 
enroll adults who lack consent capacity in research 
protocols, the report will help them ensure that 
consistent and appropriate safeguards are in place to 
protect the welfare of these vulnerable individuals. 
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will enable them to pursue research protocols that 
will lead to a better understanding of conditions that 
impair cognition. For those who already enroll adults 
who lack consent capacity in research protocols, the 
report will help them ensure that consistent and 
appropriate safeguards are in place to protect the wel-
fare of these vulnerable individuals. 
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